Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Goserelin (Zoladex) vs Histrelin (Supprelin LA / Vantas)
An educational, source-based comparison of Goserelin (Zoladex) and Histrelin (Supprelin LA / Vantas) — how each peptide works, what it's researched for, and what to know before going deeper.
Decapeptide GnRH agonist delivered via biodegradable subcutaneous implant. Suppresses gonadotropin and sex hormone production through pituitary desensitization.
- Prostate cancer
- Breast cancer (premenopausal)
- Endometriosis
- • FDA-approved.
- • Testosterone/estrogen flare; menopausal symptoms.
GnRH agonist implant for central precocious puberty and prostate cancer.
Synthetic nonapeptide GnRH agonist delivered via a subcutaneous hydrogel implant providing continuous release for 12 months, desensitizing the pituitary and suppressing sex steroids.
- Central precocious puberty (Supprelin LA)
- Advanced prostate cancer (Vantas)
- • FDA-approved.
- • Implant site reactions and rare implant breakage at removal.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Goserelin (Zoladex) | ZIPP trial | Lancet Oncology | 2005 | Adjuvant goserelin improved outcomes in premenopausal breast cancer. |
| Histrelin (Supprelin LA / Vantas) | Histrelin implant in CPP | JCEM | 2007 | Sustained suppression of pubertal progression with single annual implant. |
Side-effect & safety grid
- FDA-approved.
- Testosterone/estrogen flare; menopausal symptoms.
- FDA-approved.
- Implant site reactions and rare implant breakage at removal.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Goserelin (Zoladex) vs Histrelin (Supprelin LA / Vantas) — Key differences
- Class: Goserelin (Zoladex) is classified as GnRH Agonist · Hormonal, while Histrelin (Supprelin LA / Vantas) is GnRH Agonist · Endocrine.
- Primary research focus: Goserelin (Zoladex) — prostate cancer; Histrelin (Supprelin LA / Vantas) — central precocious puberty (supprelin la).
- Tag: FDA-Approved · Oncology vs FDA-Approved · Endocrine.